Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
Dynavax Technologies Corporation (Nasdaq: DVAX) will release its first quarter 2022 financial results on May 5, 2022, after U.S. market close. A conference call and live audio webcast are scheduled for the same day at 4:30 p.m. ET. Investors can access the webcast via the company's website or by calling (866) 420-4066. The company focuses on developing innovative vaccines, including HEPLISAV-B for hepatitis B and CpG 1018 adjuvant for various vaccines.
- Upcoming financial results may provide insights into business performance.
- Focus on developing and commercializing innovative vaccine products.
- None.
EMERYVILLE, Calif., April 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report first quarter 2022 financial results on Thursday, May 5, 2022, after the U.S. financial markets close.
Dynavax will host a conference call and live audio webcast on Thursday, May 5, 2022 at 4:30 p.m. (ET)/1:30 p.m. (PT).
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. Alternatively, participants may dial (866) 420-4066 or (409) 217-8237 and refer to conference ID 4282730. A replay of the webcast will be available for 30 days following the live event.
Dynavax is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content:https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5-2022-301526392.html
SOURCE Dynavax Technologies
FAQ
When will Dynavax report its first quarter 2022 financial results?
What time is the Dynavax conference call on May 5, 2022?
How can I access the Dynavax financial results conference call?
What products does Dynavax offer?
What is the ticker symbol for Dynavax?
